Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype‐specific, and severity‐linked alterations
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Yohannes A Ambaw und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology Program, Sloan Kettering Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Lipidomics, Lipids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Biomarkers are essential for monitoring the progression of frontotemporal dementia (FTD). Although dysregulated brain lipid metabolism, particularly sphingolipids enriched in the nervous system, is a key feature of neurodegeneration, plasma lipids remain underexplored as biomarkers compared to imaging and serum proteins. METHODS We examined plasma lipidomes using liquid chromatography–tandem mass spectrometry (LC‐MS/MS) from individuals carrying pathogenic variants linked to autosomal dominant FTD ( GRN , C9orf72 , MAPT ) and non‐carriers. RESULTS FTD subjects exhibited increased plasma levels of gangliosides (GM3(d18:1_16:0), GM3(d18:1_24:1)), ceramide Cer(d18:1_23:0), and select polyunsaturated triacylglycerols. In contrast, phosphatidylethanolamine (PE(18:0_24:0) and sphingomyelin (SM(38:0) were reduced. Subtype‐specific changes included elevated glucosylsphingosine (GlcSph(d18:1) in GRN carriers, reduced SM(34:1) in C9orf72 , and decreased TG(16:0_18:1_20:3) in MAPT carriers. GM3(d18:1_16:0) was consistently elevated across all subtypes. Furthermore, the levels of these lipids correlated with disease severity. DISCUSSION Our findings suggest that specific plasma lipid changes, notably several sphingolipids, may be useful biomarkers for FTD disease or progression. Highlights Plasma lipidomics reveals both shared and mutation‐specific lipid alterations in frontotemporal dementia (FTD). Glucosylsphingosine is specifically elevated in FTD caused by GRN mutations and correlates with disease severity. The ganglioside GM3(d18:1_16:0) is consistently elevated across GRN, MAPT, and C9orf72 variants and correlates with disease severity. Plasma sphingolipids emerge as promising biomarkers for FTD diagnosis, subtype differentiation, and disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Biology Program, Sloan Kettering Institute, New York, New York, USA.
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, USA.
- Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Present affiliation: Gene Therapy, Eli Lilly and Company, Boston, Massachusetts, USA.
- Howard Hughes Medical Institute, New York, New York, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Ambaw, Y. A., Ljubenkov, P. A., Singh, S., Hamed, A., Boland, S., Boxer, A. L., Walther, T. C., & Farese, R. V. (2025). Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype‐specific, and severity‐linked alterations. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70631
Vancouver
Ambaw YA, Ljubenkov PA, Singh S, Hamed A, Boland S, Boxer AL, et al. Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype‐specific, and severity‐linked alterations. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70631
BibTeX
@article{Ambaw2025,
author = {Ambaw, Yohannes A and Ljubenkov, Peter A and Singh, Shubham and Hamed, Abdi and Boland, Sebastian and Boxer, Adam L and Walther, Tobias C and Farese, Robert V},
title = {Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype‐specific, and severity‐linked alterations},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70631}
}
EUVIMED